Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 143
Filtrer
1.
Intern Med ; 51(5): 471-4, 2012.
Article de Anglais | MEDLINE | ID: mdl-22382561

RÉSUMÉ

Amoebiasis is a worldwide parasitic infection although it is more prevalent in the subtropical and tropical countries. Extraintestinal amoebic infections currently have been reported in increased numbers of male homosexuals and immunocompromised patients. Here, we present an interesting case of a 27-year-old homosexual man with pleural empyema secondary to rupture of amoebic liver abscess. Using chest tube and percutaneous liver abscess drainage, the patient was treated with metronidazole followed by iodoquinol. His general condition improved dramatically. After one-year of follow-up, there was no evidence of relapse on plain chest radiography and abdominal CT scan.


Sujet(s)
Empyème pleural/diagnostic , Empyème pleural/étiologie , Abcès amibien du foie/complications , Abcès amibien du foie/diagnostic , Adulte , Antiamibiens/usage thérapeutique , Drainage , Études de suivi , Humains , Diiodohydroxyquinoléine/usage thérapeutique , Abcès amibien du foie/thérapie , Mâle , Métronidazole/usage thérapeutique , Rupture spontanée/complications , Rupture spontanée/diagnostic , Rupture spontanée/thérapie , Résultat thérapeutique
2.
Parasitology ; 138(7): 819-23, 2011 Jun.
Article de Anglais | MEDLINE | ID: mdl-21524324

RÉSUMÉ

Dientamoeba fragilis is a pathogenic protozoan parasite that is implicated as a cause of human diarrhoea. A case-controlled study was conducted to determine the clinical signs associated with D. fragilis infection in children presenting to a Sydney Hospital. Treatment options are also discussed. Stool specimens were collected from children aged 15 years or younger and analysed for the presence of D. fragilis. In total, 41 children were included in the study along with a control group. Laboratory diagnosis was performed by microscopy of permanently stained, fixed faecal smears and by real-time PCR. Gastrointestinal symptoms were present in 40/41 (98%) of these children with dientamoebiasis, with diarrhoea (71%) and abdominal pain (29%) the most common clinical signs. Chronic gastrointestinal symptoms were present in 2% of cases. The most common anti-microbial used for treatment was metronidazole (n=41), with complete resolution of symptoms and clearance of parasite occurring in 85% of cases. A treatment failure rate occurred in 15% of those treated with metronidazole. Follow-up treatment comprised of an additional course of metronidazole or iodoquinol was needed in order to achieve complete resolution of infection and symptoms in this group. This study demonstrates the pathogenic potential of D. fragilis in children and as such it is recommended that all laboratories must routinely test for this organism and treat if detected.


Sujet(s)
Infection à Dientamoeba/diagnostic , Infection à Dientamoeba/traitement médicamenteux , Métronidazole/usage thérapeutique , Douleur abdominale/étiologie , Adolescent , Antiprotozoaires/usage thérapeutique , Australie/épidémiologie , Études cas-témoins , Enfant , Enfant d'âge préscolaire , Diarrhée/étiologie , Dientamoeba/physiologie , Infection à Dientamoeba/complications , Infection à Dientamoeba/épidémiologie , Infection à Dientamoeba/anatomopathologie , Fèces/parasitologie , Femelle , Humains , Nourrisson , Diiodohydroxyquinoléine/usage thérapeutique , Mâle , Résultat thérapeutique
4.
West Indian Med J ; 54(3): 210-2, 2005 Jun.
Article de Anglais | MEDLINE | ID: mdl-16209229

RÉSUMÉ

The colon responds monomorphically to a variety of insults thus making it difficult to differentiate invasive amoebic colitis and inflammatory bowel disease (IBD). The authors present a case with chronic dysentery, haematochezia, anaemia and hypoproteinaemia. The endoscopic findings were suggestive of IBD. The stool examination was negative for trophozoites or cysts of parasites. The recto-colonic biopsy specimens showed mucosal inflammation with exudates containing amoebic trophozoites. The patient was successfully treated with metronidazole and iodoquinol. He recovered within two weeks and repeat colonoscopy four weeks after the treatment showed a normal rectum and colon. Clinicians should have a high level of suspicion for amoebic colitis in cases of colitis especially in regions where amoebiasis is still present. Efforts should be made to find the amoebic trophozoites in multiple stool and colonic biopsy specimens.


Sujet(s)
Dysenterie amibienne/diagnostic , Adulte , Antiamibiens/usage thérapeutique , Diagnostic différentiel , Association de médicaments , Dysenterie amibienne/traitement médicamenteux , Humains , Maladies inflammatoires intestinales/diagnostic , Diiodohydroxyquinoléine/usage thérapeutique , Mâle , Métronidazole/usage thérapeutique
5.
West Indian med. j ; 54(3): 210-212, Jun. 2005.
Article de Anglais | LILACS | ID: lil-417392

RÉSUMÉ

The colon responds monomorphically to a variety of insults thus making it difficult to differentiate invasive amoebic colitis and inflammatory bowel disease (IBD). The authors present a case with chronic dysentery, haematochezia, anaemia and hypoproteinaemia. The endoscopic findings were suggestive of IBD. The stool examination was negative for trophozoites or cysts of parasites. The recto-colonic biopsy specimens showed mucosal inflammation with exudates containing amoebic trophozoites. The patient was successfully treated with metronidazole and iodoquinol. He recovered within two weeks and repeat colonoscopy four weeks after the treatment showed a normal rectum and colon. Clinicians should have a high level of suspicion for amoebic colitis in cases of colitis especially in regions where amoebiasis is still present. Efforts should be made to find the amoebic trophozoites in multiple stool and colonic biopsy specimens


El colon responde de manera monomórfica a una variedad de insultos, lo cual hace difícil distinguir entre la colitis amebiana invasiva y la enfermedad intestinal inflamatoria (EII). Los autores presentan un caso con disentería crónica, hematoquexia, anemia e hipoproteinemia. Los resultados endoscópicos apuntaban a una EII. El análisis de las heces fecales arrojó resultados negativos en cuanto a presencia de trofozoitos o quistes de parásitos. Esto condujo a un diagnóstico erróneo y el paciente fue tratado por una EII. Sin embargo, los especímenes de la biopsia rectocolónica mostraron una inflamación mucosal con exudados en los que se hallaban presentes trofozoitos amebianos. El paciente tuvo un tratamiento exitoso con metronidazol y iodoquinol. Se recuperó en dos semanas, y se le repitió la colonoscopia cuatro semanas después de que el tratamiento mostró un recto y colon normales. Los clínicos debían mostrar un alto nivel de sospecha ante la colitis amebiana, especialmente en aquellas regiones donde la amebiasis todavía está presente. Deben hacerse esfuerzos por encontrar trofozoitos amebianos en múltiples especímenes de heces fecales y biopsia colónica.


Sujet(s)
Humains , Mâle , Adulte , Dysenterie amibienne/diagnostic , Antiamibiens/usage thérapeutique , Diagnostic différentiel , Dysenterie amibienne/traitement médicamenteux , Maladies inflammatoires intestinales/diagnostic , Diiodohydroxyquinoléine/usage thérapeutique , Métronidazole/usage thérapeutique , Association de médicaments
6.
World J Gastroenterol ; 9(8): 1832-3, 2003 Aug.
Article de Anglais | MEDLINE | ID: mdl-12918131

RÉSUMÉ

AIM: To compare the efficacy of antibiotics therapy alone with antibiotics and saccharomyces boulardii in treatment of acute amebiasis. METHODS: In a double blind, random clinical trial on patients with acute intestinal amoebiasis, 57 adult patients with acute amoebiasis, diagnosed with clinical manifestations (acute mucous bloody diarrhea) and amebic trophozoites engulfing RBCs found in stool were enrolled in the study. Regimen 1 included metronidazole (750 mg Tid) and iodoquinol (630 mg Tid) for 10 days. Regimen 2 contained capsules of lyophilized saccharomyces boulardii (250 mg Tid) orally in addition to regimen 1. Patients were re-examined at two and four weeks after the treatment, and stool examination was performed at the end of week 4. Student's t-test, chi(2) and McNemar's tests were used for statistical analysis. RESULTS: Three patients refused to participate. The other 54 patients were randomized to receive either regimen 1 or regimen 2 (Groups 1 and 2 respectively, each with 27 patients). The two groups were similar regarding their age, sex and clinical manifestations. In Group 1, diarrhea lasted 48.0+/-18.5 hours and in Group 2, 12.0+/-3.7 hours (P<0.0001). In Group 1, the durations of fever and abdominal pain were 24.0+/-8.8 and 24.0+/-7.3 hours and in Group 2 they were 12.0+/-5.3 and 12.0+/-3.2 hours, respectively (P<0.001). Duration of headache was similar in both groups. At week 4, amebic cysts were detected in 5 cases (18.5 %) of Group 1 but in none of the Group 2 (P<0.02). CONCLUSION: Adding saccharomyces boulardii to antibiotics in the treatment of acute amebiasis seems to decrease the duration of clinical symptoms and cyst passage.


Sujet(s)
Amibiase/thérapie , Antiamibiens/usage thérapeutique , Antibactériens , Anti-infectieux/usage thérapeutique , Association de médicaments/usage thérapeutique , Diiodohydroxyquinoléine/usage thérapeutique , Métronidazole/usage thérapeutique , Probiotiques/administration et posologie , Saccharomyces , Maladie aigüe , Administration par voie orale , Capsules , Méthode en double aveugle , Humains , Résultat thérapeutique
7.
Pathol Res Pract ; 197(4): 271-4; discussion 275-8, 2001.
Article de Anglais | MEDLINE | ID: mdl-11358014

RÉSUMÉ

Entamoeba histolytica is a well-recognized cause of infectious colitis and disseminated amebic abscesses. Most prevalent in the tropics and subtropics, E. histolytica infections may also occur in the developed world. We describe a case of a North American traveler with intestinal amebiasis, a diagnosis first made by colonic biopsy. We review the available diagnostic tools and the role of the surgical pathologist in the detection of this infection.


Sujet(s)
Caecum/parasitologie , Entamoeba histolytica/isolement et purification , Infection à Entamoeba/diagnostic , Parasitoses intestinales/diagnostic , Adulte , Antiamibiens/usage thérapeutique , Animaux , Antiparasitaires/usage thérapeutique , Caecum/anatomopathologie , Coloscopie , Association de médicaments , Entamoeba histolytica/croissance et développement , Infection à Entamoeba/traitement médicamenteux , Humains , Parasitoses intestinales/traitement médicamenteux , Diiodohydroxyquinoléine/usage thérapeutique , Mâle , Métronidazole/usage thérapeutique , Résultat thérapeutique
9.
Rev. chil. infectol ; 15(2): 85-90, 1998. ilus, tab
Article de Espagnol | LILACS | ID: lil-245436

RÉSUMÉ

Se seleccionaron trabajos nacionales y extranjeros publicados para responder varias preguntas acerca de B. hominis. Se consideraron variables como edad, sexo, diagnóstico y tratamiento. Estos trabajos apoyan el rol patógeno de B. hominis. Sus manifestaciones más frecuentes son diarrea, dolor abdominal y, con menor frecuencia, meteorismo, anorexia náuseas y vómitos. Como convención entre laboratorios, se considera positivo un examen con visualización de al menos cinco parásitos por campo (40x). Metronidazol es el fármaco más efectivo para erradicar B. hominis. En los estudios revisados se reportó altas prevalencias nacionales con cifras entre 21,3 y 63,2 por ciento. Clínicos y científicos sugieren mayores estudios y vigilancia epidemiológica


Sujet(s)
Humains , Blastocystis hominis/pathogénicité , Maladies gastro-intestinales/parasitologie , Infections à Blastocystis/diagnostic , Infections à Blastocystis/traitement médicamenteux , Infections à Blastocystis/épidémiologie , Association triméthoprime-sulfaméthoxazole/usage thérapeutique , Diiodohydroxyquinoléine/usage thérapeutique , Métronidazole/usage thérapeutique
11.
Clin Infect Dis ; 20(3): 700-2, 1995 Mar.
Article de Anglais | MEDLINE | ID: mdl-7756499

RÉSUMÉ

Genital amebiasis is a rare complication of infection with Entamoeba histolytica, even in areas where the pathogen is endemic. We describe a patient who apparently contracted intestinal amebiasis on a trip to Mexico and who presented with ulcerative vulvovaginitis 2 months later. Her condition rapidly progressed to severe necrotizing vulvovaginitis that required a radical vulvectomy. Histopathologic examination of the surgical specimen revealed the presence of E. histolytica trophozoites. The patient recovered after surgery and antiamebic therapy. We review the epidemiology and pathogenesis of genital amebiasis as well as therapy for this rare infection.


Sujet(s)
Infection à Entamoeba/étiologie , Voyage , Vulvovaginite/étiologie , Sujet âgé , Animaux , Entamoeba histolytica , Infection à Entamoeba/thérapie , Femelle , Humains , Diiodohydroxyquinoléine/usage thérapeutique , Métronidazole/usage thérapeutique , Mexique , Vulvovaginite/traitement médicamenteux , Vulvovaginite/parasitologie , Vulvovaginite/chirurgie
14.
Am J Gastroenterol ; 87(6): 729-32, 1992 Jun.
Article de Anglais | MEDLINE | ID: mdl-1590309

RÉSUMÉ

Several reports have appeared that either support or deny the importance of the protozoan Blastocystis hominis as an intestinal pathogen in humans. In this report, we describe the clinical characteristics of B. hominis and its response to therapy in hospital employees found to have the parasite on routine screening of stools. During the study, 49 patients with B. hominis were identified, and 413 stools were examined from these patients. Twenty-nine patients were asymptomatic (59%), and 20 had symptoms of bloating, flatulence, soft/loose stools, or constipation. Of these 20 patients, 10 had symptoms that correlated with the presence or absence of B. hominis, four had symptoms that were independent of B. homonis, and six had other intestinal parasites that could account for their symptoms. Nineteen percent of patients without treatment had eradication of B. hominis from stool on follow-up examination. Metronidazole did not increase this rate. Iodoquinol treatment eradicated the organism in 41% of patients (p less than 0.05), and resulted in the reduction or eradication of the parasite in 62%, as determined by follow-up examination.


Sujet(s)
Infections à Blastocystis/parasitologie , Blastocystis hominis/isolement et purification , Personnel hospitalier , Adolescent , Adulte , Sujet âgé , Animaux , Infections à Blastocystis/traitement médicamenteux , Services de diététique et de nutrition , Fèces/parasitologie , Femelle , Études de suivi , Humains , Diiodohydroxyquinoléine/usage thérapeutique , Mâle , Métronidazole/usage thérapeutique , Adulte d'âge moyen , Personnel infirmier hospitalier
16.
Invest. med. int ; 18(4): 188-9, ene. 1992.
Article de Espagnol | LILACS | ID: lil-117812

RÉSUMÉ

Se estudió la evolución de 60 pacientes escolares con diagnóstico clínico de colitis amebiana, habitantes de una zona rural llamada Xico. La muestra se dividió en dos grupos, 30 del sexo femenino y 30 del masculino con edades entre seis y 12 años. Se administró una combinación de diyodohidroxiquinoleína y dimeticona a dosis de 30 mg por kg por día por vía oral en forma de suspensión. A los 4.5 días promedio hubo notable mejoría en 93.7 por ciento de los pacientes, por lo que concluye que esta combinación es una alternativa empírica eficaz para el tratamiento de la colitis amebiana.


Sujet(s)
Humains , Mâle , Femelle , Dysenterie amibienne/traitement médicamenteux , Diiodohydroxyquinoléine/usage thérapeutique , Mexique , Siméticone/usage thérapeutique
19.
Invest. med. int ; 16(4): 251-3, feb. 1990. tab
Article de Espagnol | LILACS | ID: lil-95543

RÉSUMÉ

Se trataron con diyodohidroxiquinoleina 53 niños de ambos sexos, en edad comprendida entre cinco y 17 años, atendidos en la consulta externa del servicio de parasitología del Instituto Nacional de Pediatía, en los cuales se diagnosticó amebiasis intestinal no invasiva en fase clínica y por exámenes de laboratorio (CPS) Faust). El fármaco se administró a razón de 30 mg/kg/dpia 10 días. Hubo curación en el 98.1% sólo dos pacientes refirieron efectos advrsos atribuidos al medicamento, uno presentó diarrea y otro náusea. Los resultados obtenidos permiten recomendar el uso de diyodohidroxiquinoleína en el tratamiento de la amebiasis intestinal no invasiva en niños con un esquema más corto que el convencional, que disminuye la presentación de efectos adversos y abatimiento del costo


Sujet(s)
Humains , Enfant d'âge préscolaire , Enfant , Adolescent , Mâle , Femelle , Amibiase/thérapie , Diiodohydroxyquinoléine/administration et posologie , Diiodohydroxyquinoléine/effets indésirables , Diiodohydroxyquinoléine/usage thérapeutique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE